GILEAD SCIENCES INC

NASDAQ: GILD (Gilead Sciences, Inc.)

Kemas kini terakhir: 5 hari lalu, 9:18AM

102.17

-1.02 (-0.99%)

  • 1H -0.99%
  • 5H -8.69%
  • 1B -8.32%
  • 6B 20.13%
  • Tahun Ke Tarikh 11.20%
  • 1T 50.80%
  • 5T 31.41%
Penutupan Terdahulu 103.19
Buka 97.97
Jumlah Dagangan 2,712,785
Purata Dagangan (3B) 9,078,127
Modal Pasaran 127,368,183,808
Harga / Pendapatan (P/E TTM) 268.87
Harga / Pendapatan (P/E Ke hadapan) 14.16
Harga / Jualan (P/S) 4.88
Harga / Buku (P/B) 7.22
Julat 52 Minggu
62.07 (-39%) — 119.96 (17%)
Tarikh Pendapatan 24 Apr 2025
Hasil Dividen (DY TTM) 3.03%
Margin Keuntungan 1.67%
Margin Operasi (TTM) 33.07%
EPS Cair (TTM) 0.380
Pertumbuhan Hasil Suku Tahunan (YOY) 6.40%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 24.80%
Jumlah Hutang/Ekuiti (D/E MRQ) 141.96%
Nisbah Semasa (MRQ) 1.60
Aliran Tunai Operasi (OCF TTM) 10.83 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 10.13 B
Pulangan Atas Aset (ROA TTM) 11.03%
Pulangan Atas Ekuiti (ROE TTM) 2.29%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Bercampur Menaik
Drug Manufacturers - General (Global) Bercampur Menaik
Stok Gilead Sciences, Inc. Menaik Menaik

AISkor Stockmoo

-0.8
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam NA
Volatiliti Harga -0.5
Purata Bergerak Teknikal -3.5
Osilator Teknikal -0.5
Purata -0.75

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
GILD 127 B 3.03% 268.87 7.22
AMGN 154 B 3.19% 37.88 26.14
AZN 230 B 2.26% 30.43 6.19
SNY 127 B 7.86% 21.51 1.48
GRFS 6 B - 28.00 0.710
BIIB 21 B - 12.64 1.01

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Value
% Dimiliki oleh Orang Dalam 0.12%
% Dimiliki oleh Institusi 89.59%
128.70128.70111.60111.6094.5094.5077.4077.4060.3060.30Harga Sasaran MedianQ2 '20Q2 '20Q3 '20Q3 '20Q4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25
Julat 52 Minggu
62.07 (-39%) — 119.96 (17%)
Julat Harga Sasaran
90.00 (-11%) — 140.00 (37%)
Tinggi 140.00 (Wells Fargo, 37.03%) Beli
Median 123.00 (20.39%)
Rendah 90.00 (RBC Capital, -11.91%) Pegang
Purata 118.90 (16.38%)
Jumlah 8 Beli, 2 Pegang
Harga Purata @ Panggilan 108.97
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
JP Morgan 27 Mar 2025 130.00 (27.24%) Beli 111.16
29 Jan 2025 115.00 (12.56%) Beli 95.59
Morgan Stanley 11 Mar 2025 130.00 (27.24%) Beli 114.43
12 Feb 2025 123.00 (20.39%) Beli 103.31
B of A Securities 05 Mar 2025 126.00 (23.32%) Beli 115.44
Wells Fargo 05 Mar 2025 140.00 (37.03%) Beli 115.44
12 Feb 2025 120.00 (17.45%) Beli 103.31
Oppenheimer 04 Mar 2025 132.00 (29.20%) Beli 114.74
Deutsche Bank 18 Feb 2025 120.00 (17.45%) Beli 105.25
BMO Capital 12 Feb 2025 115.00 (12.56%) Beli 103.31
Goldman Sachs 12 Feb 2025 96.00 (-6.04%) Pegang 103.31
Piper Sandler 12 Feb 2025 110.00 (7.66%) Beli 103.31
RBC Capital 12 Feb 2025 90.00 (-11.91%) Pegang 103.31
03 Feb 2025 84.00 (-17.78%) Pegang 98.38
Papar semua

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
10 Apr 2025 Pengumuman Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025
12 Mar 2025 Pengumuman Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
11 Mar 2025 Pengumuman First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
24 Feb 2025 Pengumuman European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention
20 Feb 2025 Pengumuman Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
19 Feb 2025 Pengumuman Gilead Sciences to Present at Upcoming Investor Conferences
18 Feb 2025 Pengumuman U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
13 Feb 2025 CNBC U.S. investors, Big Pharma race to find new medicines in China
11 Feb 2025 Pengumuman Gilead Sciences Announces 2.6 Percent Increase in First Quarter 2025 Dividend
11 Feb 2025 Pengumuman Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results
30 Jan 2025 Pengumuman Cognizant and Gilead Expand Partnership to Drive Greater Value Through Advanced Technology Applications
28 Jan 2025 Pengumuman Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025
Papar semua
Hasil Dividen (DY TTM) 3.03%
Purata Hasil Dividen 5T 3.80%
Nisbah Pembayaran 810.53%
Jangkaan Pembayaran Dividen Seterusnya Jun 2025
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
14 Mar 2025 05 Feb 2025 28 Mar 2025 0.79 Tunai
13 Dec 2024 30 Oct 2024 30 Dec 2024 0.77 Tunai
13 Sep 2024 30 Jul 2024 27 Sep 2024 0.77 Tunai
14 Jun 2024 23 Apr 2024 27 Jun 2024 0.77 Tunai
14 Mar 2024 01 Feb 2024 28 Mar 2024 0.77 Tunai
14 Dec 2023 01 Nov 2023 28 Dec 2023 0.75 Tunai
14 Sep 2023 25 Jul 2023 28 Sep 2023 0.75 Tunai
14 Jun 2023 25 Apr 2023 29 Jun 2023 0.75 Tunai
14 Mar 2023 25 Jan 2023 30 Mar 2023 0.75 Tunai
14 Dec 2022 25 Oct 2022 29 Dec 2022 0.73 Tunai
14 Sep 2022 25 Jul 2022 29 Sep 2022 0.73 Tunai
14 Jun 2022 27 Apr 2022 29 Jun 2022 0.73 Tunai
14 Mar 2022 28 Jan 2022 30 Mar 2022 0.73 Tunai
14 Dec 2021 26 Oct 2021 30 Dec 2021 0.71 Tunai
14 Sep 2021 26 Jul 2021 29 Sep 2021 0.71 Tunai
14 Jun 2021 27 Apr 2021 29 Jun 2021 0.71 Tunai
12 Mar 2021 02 Feb 2021 30 Mar 2021 0.71 Tunai
14 Dec 2020 26 Oct 2020 30 Dec 2020 0.68 Tunai
14 Sep 2020 29 Jul 2020 29 Sep 2020 0.68 Tunai
11 Jun 2020 29 Apr 2020 29 Jun 2020 0.68 Tunai
12 Mar 2020 03 Feb 2020 30 Mar 2020 0.68 Tunai
12 Dec 2019 23 Oct 2019 30 Dec 2019 0.63 Tunai
12 Sep 2019 29 Jul 2019 27 Sep 2019 0.63 Tunai
13 Jun 2019 01 May 2019 27 Jun 2019 0.63 Tunai
14 Mar 2019 01 Feb 2019 28 Mar 2019 0.63 Tunai
13 Dec 2018 24 Oct 2018 28 Dec 2018 0.57 Tunai
13 Sep 2018 24 Jul 2018 27 Sep 2018 0.57 Tunai
14 Jun 2018 30 Apr 2018 28 Jun 2018 0.57 Tunai
15 Mar 2018 05 Feb 2018 29 Mar 2018 0.57 Tunai
14 Dec 2017 25 Oct 2017 28 Dec 2017 0.52 Tunai
14 Sep 2017 25 Jul 2017 28 Sep 2017 0.52 Tunai
14 Jun 2017 01 May 2017 29 Jun 2017 0.52 Tunai
14 Mar 2017 06 Feb 2017 30 Mar 2017 0.52 Tunai
13 Dec 2016 31 Oct 2016 29 Dec 2016 0.47 Tunai
14 Sep 2016 22 Jul 2016 29 Sep 2016 0.47 Tunai
14 Jun 2016 27 Apr 2016 29 Jun 2016 0.47 Tunai
14 Mar 2016 02 Feb 2016 30 Mar 2016 0.43 Tunai
14 Dec 2015 26 Oct 2015 30 Dec 2015 0.43 Tunai
14 Sep 2015 23 Jul 2015 29 Sep 2015 0.43 Tunai
12 Jun 2015 24 Apr 2015 29 Jun 2015 0.43 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 0.790 1 0.77
2024 3.08 4 3.33
2023 3.00 4 3.70
2022 2.92 4 3.40
2021 2.84 4 3.91
2020 2.72 4 4.67
2019 2.52 4 3.88
2018 2.28 4 3.65
2017 2.08 4 2.90
2016 1.84 4 2.57
2015 1.29 3 1.28
Papar semua
116.49116.49109.52109.52102.55102.5595.5895.5888.6188.61Mar 31Mar 31Apr 1Apr 1Apr 2Apr 2Apr 3Apr 3Apr 4Apr 4Apr 7Apr 7Apr 8Apr 8Apr 9Apr 9

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
3.0003.0002.0002.0001.0001.0000.0000.000-1.000-1.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda